Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04240054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

Study acronym: VICD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv14
  2. Primary completion date: Dec 1, 2025 to Dec 1, 2029 Study sites: 2 to 1 · Completion date: Dec 1, 2026 to Dec 1, 2030 · Study arms: 3 to 2 · 2 morev13 Show 5 more changesShow less
    • Study sites: 2 to 1
    • Completion date: Dec 1, 2026 to Dec 1, 2030
    • Study arms: 3 to 2
    • Eligibility criteria shortened, about 2 words
    • Study title expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 3 to 2v12
  4. Eligibility criteria expanded, about 51 words Secondary endpoints: details revised at 1 of 2 entries · Site details revised at 1 of 3 sitesv11 Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 1 of 3 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Site details revised at 1 of 3 sitesv10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 2 to 3 Secondary endpoints: 5 to 2v9 Show 1 more changeShow less
    • Secondary endpoints: 5 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 1 to 2 Eligibility criteria expanded, about 26 wordsv8 Show 1 more changeShow less
    • Eligibility criteria expanded, about 26 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jan 1, 2022 to Nov 2, 2021v7 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 1, 2022 to Nov 2, 2021
  4. Primary completion date: Dec 1, 2024 to Dec 1, 2025 Start date: Sep 1, 2021 to Jan 1, 2022 · Completion date: Dec 1, 2025 to Dec 1, 2026v6 Show 2 more changesShow less
    • Start date: Sep 1, 2021 to Jan 1, 2022
    • Completion date: Dec 1, 2025 to Dec 1, 2026
  5. Start date: Jun 1, 2021 to Sep 1, 2021v5
  6. Primary completion date: Dec 1, 2023 to Dec 1, 2024 Completion date: Dec 1, 2024 to Dec 1, 2025v4 Show 1 more changeShow less
    • Completion date: Dec 1, 2024 to Dec 1, 2025
  7. Primary completion date: Dec 1, 2022 to Dec 1, 2023 Start date: Jun 1, 2020 to Jun 1, 2021 · Completion date: Dec 1, 2023 to Dec 1, 2024 · Study title shortened, about 3 wordsv3 Show 3 more changesShow less
    • Start date: Jun 1, 2020 to Jun 1, 2021
    • Completion date: Dec 1, 2023 to Dec 1, 2024
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, open-label phase II study with a safety lead-in phase.
Trial Details
NCT Number NCT04240054
Lead Sponsor Medical College of Wisconsin
Conditions Multiple Myeloma
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov